Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Apr 08, 2025, 07:30 ET First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection ANNAPOLIS, Md., April 8,…
Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 10, 2025, 07:30 ET Phase 2a clinical program demonstrates safety and efficacy for all endpoints in AD with and without secondary infection ANNAPOLIS, Md. and ORLANDO, Fla., March 10, 2025 /PRNewswire/ — Alphyn,…
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Feb 19, 2025, 07:30 ET Zabalafin Hydrogel holds potential for first comprehensive AD treatment with safety and patient tolerability profile for long-term, worry-free, continuous use ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company…
Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…
Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…